Trial Profile
Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2015
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Thrombotic microangiopathy
- Focus Therapeutic Use
- 03 Nov 2015 New trial record